加载中
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
常规交易时段
US$1.76
−US$0.09 · -4.86%
盘中时间采用ET。市场数据可能有所延迟。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日内区间
当前US$1.76
52周区间
当前US$1.76
盘中时间采用ET。市场数据可能有所延迟。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日内区间
当前US$1.76
52周区间
当前US$1.76
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.83
上涨空间 572.16%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI112.16万0.00%2.3万亿 USD0.03%US$380.35-0.18%
iShares Russell 2000 ETFIWM60.12万0.00%785.63亿 USD0.19%US$275.82-0.68%
Vanguard Extended Market ETFVXF38.77万0.00%954亿 USD0.05%US$232.32-0.50%
iShares Russell 2000 Growth ETFIWO22.71万0.00%142.49亿 USD0.24%US$351.6-1.06%
Vanguard Russell 2000 ETFVTWO20.43万0.00%180亿 USD0.06%US$111.38-0.74%
iShares Micro-Cap ETFIWC9.28万0.01%13.33亿 USD0.60%US$181.72-0.89%
Vanguard Russell 2000 Growth ETFVTWG3.8万0.00%17亿 USD0.06%US$256.87-0.94%
iShares Russell 2500 ETFSMMD1.26万0.00%40.61亿 USD0.23%US$85.385-0.54%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
